What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).”In the company’s words, NCT05499013 on ClinicalTrials.gov
- Tested for
- Polycythemia Vera
- Main trialPhase 1/2
- “This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.”In the company’s words, NCT05499013 on ClinicalTrials.gov
Other drugs for Polycythemia Vera
- GivinostatItalfarmaco · Phase 3
- RusfertideProtagonist Therapeutics, Inc. · Phase 3
- AG-236Agios Pharmaceuticals, Inc. · Phase 2/3
- BomedemstatMerck & Co. · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- Flonoltinib MaleateChengdu Zenitar Biomedical Technology Co., Ltd · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Sep 2026 | Study to Assess SLN124 in Patients With Polycythemia Vera | |
| Phase 1Completed | 23 May 2023 | A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026